Tree News

BUSINESSWIRE · 2026-11-04 14:15 UTC

Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026

Gilead and Kite announced 23 presentations at ASH 2026, including 7 oral presentations, featuring new clinical data across their pipeline. iMMagine-1 trial will present 18-month minimum follow-up data on anito-cel in relapsed/refractory multiple myeloma, with FDA BLA under review with PDUFA target date of December 23, 2026. ZUMA-12 five-year follow-up data will be presented for Yescarta in first-line high-risk large B-cell lymphoma, alongside expanded real-world evidence from multiple registries.

Loading the story on Tree News…